


**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-8 (Cancelled).

9. (New): A compound of formula (I):



wherein:

$R^1$  represents  $-C_{1-6}$  alkyl substituted by 1, 2, or 3 halogen or cyano groups;  $-C_{0-4}$  alkyl- $C_{3-8}$ cycloalkyl;  $-C_{2-4}$  alkyl-oxy- $C_{1-4}$  alkyl;  $-C_{1-4}$  alkyl-aryl, wherein said cycloalkyl or aryl groups of  $R^1$  may be optionally substituted by 1, 2, or 3 groups selected from halogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, cyano, amino and trifluoromethyl;

$R^2$  represents hydrogen or  $C_{1-6}$  alkyl;

$m$  represents 1;

$R^3$  represents hydrogen, methyl or halogen;

$R^4$  and  $R^5$  independently represent hydrogen or methyl;

$n$  represents 1;

$p$  represents 1 or 2;

A represents phenyl optionally substituted by a halogen, cyano, trifluoromethyl, or trifluoromethoxy group;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

10. (New): The compound according to claim 9, wherein: A is unsubstituted phenyl.
11. (New): A compound which is:
- 8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
  - 8-(4-Cyclopropylmethyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
  - 8-(4-(Cyclohexyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
  - 8-(4-Cyclopentyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
  - 8-(4-Cyclobutyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
  - 8-(4-Cyclopropyl-piperazin-1-yl)-3-phenylsulfonylquinoline;
  - 8-(4-(2-methoxyethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
  - 8-(4-(2,2,2-Trifluoroethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;
- or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
12. (New): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 9 and a pharmaceutically acceptable carrier or excipient.
13. (New): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 11 and a pharmaceutically acceptable carrier or excipient.
14. (New): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 9 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.
15. (New): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 11 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.

16. (New): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

17. (New): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.

18. (New): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

19. (New): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.

20. (New): A method of Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

21. (New): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 11.